![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines – a more than fivefold increase over the last decade, including Acetaminophen injection.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Product Name: Acetaminophen-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: $425.0 million Upfront Cash: $375.0 million
Deal Type: Acquisition April 21, 2022
Details:
The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated US portfolio to close to 130 commercialised injectable medicines including Acetaminophen injection– a more than fivefold increase over the last decade.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Product Name: Acetaminophen-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: $425.0 million Upfront Cash: $375.0 million
Deal Type: Acquisition September 27, 2021